PMID- 32639288
OWN - NLM
STAT- MEDLINE
DCOM- 20210121
LR  - 20220420
IS  - 1533-712X (Electronic)
IS  - 0271-0749 (Linking)
VI  - 40
IP  - 4
DP  - 2020 Jul/Aug
TI  - Antidepressants and Risk of Type 2 Diabetes Mellitus: A Population-Based Nested 
      Case-Control Study.
PG  - 359-365
LID - 10.1097/JCP.0000000000001228 [doi]
AB  - PURPOSE/BACKGROUND: The increased risk of type 2 diabetes mellitus (T2DM) among 
      users of antidepressants (ADs) might be mediated by depression. We investigated 
      whether ADs are associated with increased risk of T2DM in patients with 
      depression. Moreover, the relationship between binding affinities of serotonin 
      transporter (SERT) of ADs and the risk of T2DM is examined. METHODS/PROCEDURES: 
      We conducted a retrospective nested case-control study using data from Taiwan's 
      National Health Insurance Research Database between 2000 and 2013. A total of 
      3038 patients with depression, 1519 cases of T2DM, and 1519 controls matched for 
      age, sex, and index date, were included. Exposure to ADs was categorized by type 
      and SERT. The association between AD exposure and T2DM development was assessed 
      using conditional logistic regression analysis. FINDINGS/RESULTS: No association 
      between T2DM development and selective serotonin reuptake inhibitors (adjusted 
      odds ratio [AOR], 1.01; 95% confidence interval [CI], 0.87-1.19; P = 0.962), 
      serotonin-norepinephrine reuptake inhibitors (AOR, 1.13; 95% CI, 0.94-1.37; P = 
      1.196), tricyclic antidepressants (AOR, 1.01; 95% CI, 0.85-1.21; P = 0.906), or 
      others (AOR, 0.88; 95% CI, 0.75-1.03; P = 0.104) was found. Alternatively, no 
      association between individual ADs and potency of affinity to SERT and the risk 
      of T2DM was found. IMPLICATIONS/CONCLUSIONS: No association between ADs and 
      increase risk of T2DM was found in patients with depression. However, regular 
      metabolic evaluations are recommended for patients with depression regularly 
      taking ADs.
FAU - Kuo, Hsin-Ya
AU  - Kuo HY
AD  - From the Departments of Psychiatry.
FAU - Chen, Hsiu-Min
AU  - Chen HM
FAU - Lee, Ching-Chih
AU  - Lee CC
FAU - Lee, Hsuan-Han
AU  - Lee HH
AD  - From the Departments of Psychiatry.
FAU - Kuo, Chuan-Jung
AU  - Kuo CJ
AD  - Department of Psychiatry, National Cheng Kung University Hospital, Tainan City.
FAU - Hsu, Chun-Sheng
AU  - Hsu CS
FAU - Pan, Chih-Chuan
AU  - Pan CC
AD  - From the Departments of Psychiatry.
FAU - Su, Ning
AU  - Su N
AD  - Drkuo Clinic.
FAU - Chu, Che-Sheng
AU  - Chu CS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Psychopharmacol
JT  - Journal of clinical psychopharmacology
JID - 8109496
RN  - 0 (Antidepressive Agents)
RN  - 0 (Serotonin Plasma Membrane Transport Proteins)
SB  - IM
MH  - Antidepressive Agents/*adverse effects/pharmacology
MH  - Case-Control Studies
MH  - Databases, Factual
MH  - Depression/drug therapy
MH  - Diabetes Mellitus, Type 2/*chemically induced
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Protein Binding/drug effects
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Serotonin Plasma Membrane Transport Proteins/metabolism
EDAT- 2020/07/09 06:00
MHDA- 2021/01/22 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2021/01/22 06:00 [medline]
AID - 00004714-202007000-00009 [pii]
AID - 10.1097/JCP.0000000000001228 [doi]
PST - ppublish
SO  - J Clin Psychopharmacol. 2020 Jul/Aug;40(4):359-365. doi: 
      10.1097/JCP.0000000000001228.